Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with…
Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and…
Read More...
Read More...